Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer

This is a single-arm Phase II clinical trial assessing the clinical efficacy of prostate specific membrane antigen (PSMA) PET/MR guided MR-LINAC based SBRT-SIB with planned accrual of 50 patients.

Trial Details

NCT ID

NCT04402151

Phase

PHASE2

Sponsor

Weill Medical College of Cornell University

Status

RECRUITING

Cancer Type

Prostate Cancer

Interventions

PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC
Stereotactic Body Radiation Therapy (SBRT)

Locations (sample)

New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

Male aged 21 years or older.
Ability to provide signed informed consent and willingness to comply with protocol requirements.
Pathologic confirmation of high-risk adenocarcinoma of the prostate gland as follows: a. Gleason 8-10 or tertiary component 5 disease and/or b. PSA…
Participants must agree to use an acceptable form of birth control and utilize condoms for a period of seven days after each PSMA injection, if eng…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →